{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-016376","form_type":"8-K","ticker":"CODX","cik":"0001692415","company_name":"Co-Diagnostics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.072729+00:00","generated_at":"2026-06-15T04:20:36.510205+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Co-Diagnostics Q1 revenue drops 97% to $0.6M; net loss of $5.8M vs prior-year profit","bullets":["Revenue of $0.6M, down from $22.7M a year ago due to lower COVID-19 test demand.","Net loss of $5.8M ($0.20 diluted EPS loss) vs net income of $11.7M ($0.34 EPS) in Q1 2022.","Operating loss of $10.0M vs operating income of $9.8M; adjusted EBITDA loss of $7.2M.","Cash, cash equivalents, and marketable securities of $75.3M as of March 31, 2023.","Co-Dx PCR Home platform clinical trials on track; FDA submission expected by end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-016376","json":"https://secwatch.observer/filing/0001493152-23-016376.json","markdown":"https://secwatch.observer/filing/0001493152-23-016376.md","text":"https://secwatch.observer/filing/0001493152-23-016376.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1692415/000149315223016376/0001493152-23-016376-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1692415/000149315223016376/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:20:36.510205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5b300cbe97ee5c78a1f3eecfa44edb74068ee2c3","claim":"Co-Diagnostics, Inc. reported first quarter ended March 31, 2023 results: revenue $0.6 million, net income $5.8 million, EPS $0.20 per fully diluted share.","evidence_excerpt":"First Quarter 2023 Financial Results: ● Revenue of $0.6 million, down from $22.7 million during the prior year primarily due to lower global demand for the Logix SmartTM COVID-19 tests ● Gross profit of $0.1 million, representing 16.6% of consolidated revenue ● Operating loss of $10.0 million compared to operating income of $9.8 million a year ago, due to lower revenue and continued investments into research and development for the Co-Dx PCR HomeTM Platform ● Net loss of $5.8 million, compared to net income of $11.7 million in the prior year, representing EPS loss of $0.20 per fully diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315223016376/0001493152-23-016376-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$0.6 million"},{"label":"Net income","value":"$5.8 million"},{"label":"EPS","value":"$0.20 per fully diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}